18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases

Emirhan Nemutlu, Song Zhang, Nenad O. Juranic, Andre Terzic, Slobodan I Macura, Petras P Dzeja

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Technological innovations and translation of basic discoveries to clinical practice drive advances in medicine. Today's innovative technologies enable comprehensive screening of the genome, transcriptome, proteome, and metabolome. The detailed knowledge, converged in the integrated "omics" (genomics, transcriptomics, proteomics, and metabolomics), holds an immense potential for understanding mechanism of diseases, facilitating their early diagnostics, selecting personalized therapeutic strategies, and assessing their effectiveness. Metabolomics is the newest "omics" approach aimed to analyze large metabolite pools. The next generation of metabolomic screening requires technologies for high throughput and robust monitoring of metabolite levels and their fluxes. In this regard, stable isotope 18O-based metabolite tagging technology expands quantitative measurements of metabolite levels and turnover rates to all metabolites that include water as a reactant, most notably phosphometabolites. The obtained profiles and turnover rates are sensitive indicators of energy and metabolic imbalances like the ones created by genetic deficiencies, myocardial ischemia, heart failure, neurodegenerative disorders, etc. Here we describe and discuss briefly the potential use of dynamic phosphometabolomic platform for disease diagnostics currently under development at Mayo Clinic.

Original languageEnglish (US)
Pages (from-to)529-534
Number of pages6
JournalCroatian Medical Journal
Volume53
Issue number6
DOIs
StatePublished - 2012

Fingerprint

Metabolomics
Technology
Inventions
Metabolome
Proteome
Genomics
Transcriptome
Isotopes
Neurodegenerative Diseases
Proteomics
Myocardial Ischemia
Heart Failure
Medicine
Genome
Water
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases. / Nemutlu, Emirhan; Zhang, Song; Juranic, Nenad O.; Terzic, Andre; Macura, Slobodan I; Dzeja, Petras P.

In: Croatian Medical Journal, Vol. 53, No. 6, 2012, p. 529-534.

Research output: Contribution to journalArticle

@article{defa6cc7406e4493b23c09a5b164083e,
title = "18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases",
abstract = "Technological innovations and translation of basic discoveries to clinical practice drive advances in medicine. Today's innovative technologies enable comprehensive screening of the genome, transcriptome, proteome, and metabolome. The detailed knowledge, converged in the integrated {"}omics{"} (genomics, transcriptomics, proteomics, and metabolomics), holds an immense potential for understanding mechanism of diseases, facilitating their early diagnostics, selecting personalized therapeutic strategies, and assessing their effectiveness. Metabolomics is the newest {"}omics{"} approach aimed to analyze large metabolite pools. The next generation of metabolomic screening requires technologies for high throughput and robust monitoring of metabolite levels and their fluxes. In this regard, stable isotope 18O-based metabolite tagging technology expands quantitative measurements of metabolite levels and turnover rates to all metabolites that include water as a reactant, most notably phosphometabolites. The obtained profiles and turnover rates are sensitive indicators of energy and metabolic imbalances like the ones created by genetic deficiencies, myocardial ischemia, heart failure, neurodegenerative disorders, etc. Here we describe and discuss briefly the potential use of dynamic phosphometabolomic platform for disease diagnostics currently under development at Mayo Clinic.",
author = "Emirhan Nemutlu and Song Zhang and Juranic, {Nenad O.} and Andre Terzic and Macura, {Slobodan I} and Dzeja, {Petras P}",
year = "2012",
doi = "10.3325/cmj.2012.53.529",
language = "English (US)",
volume = "53",
pages = "529--534",
journal = "Croatian Medical Journal",
issn = "0353-9504",
publisher = "Medicinska Naklada d.o.o",
number = "6",

}

TY - JOUR

T1 - 18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases

AU - Nemutlu, Emirhan

AU - Zhang, Song

AU - Juranic, Nenad O.

AU - Terzic, Andre

AU - Macura, Slobodan I

AU - Dzeja, Petras P

PY - 2012

Y1 - 2012

N2 - Technological innovations and translation of basic discoveries to clinical practice drive advances in medicine. Today's innovative technologies enable comprehensive screening of the genome, transcriptome, proteome, and metabolome. The detailed knowledge, converged in the integrated "omics" (genomics, transcriptomics, proteomics, and metabolomics), holds an immense potential for understanding mechanism of diseases, facilitating their early diagnostics, selecting personalized therapeutic strategies, and assessing their effectiveness. Metabolomics is the newest "omics" approach aimed to analyze large metabolite pools. The next generation of metabolomic screening requires technologies for high throughput and robust monitoring of metabolite levels and their fluxes. In this regard, stable isotope 18O-based metabolite tagging technology expands quantitative measurements of metabolite levels and turnover rates to all metabolites that include water as a reactant, most notably phosphometabolites. The obtained profiles and turnover rates are sensitive indicators of energy and metabolic imbalances like the ones created by genetic deficiencies, myocardial ischemia, heart failure, neurodegenerative disorders, etc. Here we describe and discuss briefly the potential use of dynamic phosphometabolomic platform for disease diagnostics currently under development at Mayo Clinic.

AB - Technological innovations and translation of basic discoveries to clinical practice drive advances in medicine. Today's innovative technologies enable comprehensive screening of the genome, transcriptome, proteome, and metabolome. The detailed knowledge, converged in the integrated "omics" (genomics, transcriptomics, proteomics, and metabolomics), holds an immense potential for understanding mechanism of diseases, facilitating their early diagnostics, selecting personalized therapeutic strategies, and assessing their effectiveness. Metabolomics is the newest "omics" approach aimed to analyze large metabolite pools. The next generation of metabolomic screening requires technologies for high throughput and robust monitoring of metabolite levels and their fluxes. In this regard, stable isotope 18O-based metabolite tagging technology expands quantitative measurements of metabolite levels and turnover rates to all metabolites that include water as a reactant, most notably phosphometabolites. The obtained profiles and turnover rates are sensitive indicators of energy and metabolic imbalances like the ones created by genetic deficiencies, myocardial ischemia, heart failure, neurodegenerative disorders, etc. Here we describe and discuss briefly the potential use of dynamic phosphometabolomic platform for disease diagnostics currently under development at Mayo Clinic.

UR - http://www.scopus.com/inward/record.url?scp=84872787318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872787318&partnerID=8YFLogxK

U2 - 10.3325/cmj.2012.53.529

DO - 10.3325/cmj.2012.53.529

M3 - Article

C2 - 23275318

AN - SCOPUS:84872787318

VL - 53

SP - 529

EP - 534

JO - Croatian Medical Journal

JF - Croatian Medical Journal

SN - 0353-9504

IS - 6

ER -